Skip to main content
Premium Trial:

Request an Annual Quote

CombiMatrix Regains Nasdaq Listing Compliance

NEW YORK (GenomeWeb News) – CombiMatrix today said that it has regained compliance with a Nasdaq listing requirement calling for at least $2.5 million in stockholders' equity.

The Director of Listing Qualifications informed the Irvine, Calif.-based firm of its compliance in a letter dated Aug. 20, saying that based on CombiMatrix's Form 10-Q for the second quarter, which indicated that it had stockholders' equity of $5.7 million, the Nasdaq staff determined that the company was in compliance and "the matter is now closed."

CombiMatrix was warned by Nasdaq of its non-compliance in March, and it originally gave the firm until April 25 to submit a plan to regain compliance. The plan was submitted, and in May Nasdaq extended the deadline under which CombiMatrix had to provide evidence that it was in compliance with the Nasdaq rule.

Earlier this month, the company reported a 15 percent jump in its second quarter revenues.

The Scan

Ancient Greek Army Ancestry Highlights Mercenary Role in Historical Migrations

By profiling genomic patterns in 5th century samples from in and around Himera, researchers saw diverse ancestry in Greek army representatives in the region, as they report in PNAS.

Estonian Biobank Team Digs into Results Return Strategies, Experiences

Researchers in the European Journal of Human Genetics outline a procedure developed for individual return of results for the population biobank, along with participant experiences conveyed in survey data.

Rare Recessive Disease Insights Found in Individual Genomes

Researchers predict in Genome Medicine cross-population deletions and autosomal recessive disease impacts by analyzing recurrent nonallelic homologous recombination-related deletions.

Genetic Tests Lead to Potential Prognostic Variants in Dutch Children With Dilated Cardiomyopathy

Researchers in Circulation: Genomic and Precision Medicine found that the presence of pathogenic or likely pathogenic variants was linked to increased risk of death and poorer outcomes in children with pediatric dilated cardiomyopathy.